Want to see RYTM full AI Analyst Report?
RYTM Stock Chart & Stats
$113.35
-$0.56(-0.55%)
At close: 4:00 PM EDT
$113.35
-$0.56(-0.55%)
Day’s Range― - ―
52-Week Range$74.50 - $122.20
Previous CloseN/A
Volume467.13K
Average Volume (3M)717.88K
Market Cap
$5.93B
Enterprise Value$7.51B
Total Cash (Recent Filing)$330.90M
Total Debt (Recent Filing)$3.68M
Price to Earnings (P/E)―
Beta1.78
Next Earnings
Nov 10, 2026EPS Estimate
-0.71Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.11
Shares Outstanding68,852,080
10 Day Avg. Volume813,415
30 Day Avg. Volume717,883
Financial Highlights & Ratios
PEG Ratio1.21
Price to Book (P/B)25.76
Price to Sales (P/S)36.66
P/FCF Ratio-59.64
Enterprise Value/Market Cap1.27
Enterprise Value/Revenue31.30
Enterprise Value/Gross Profit35.17
Enterprise Value/Ebitda-40.65
Forecast
1Y Price Target
$146.38Price Target Upside29.14% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
EPS Forecast (FY)-2.95
Revenue Forecast (FY)$318.26M
Bulls Say, Bears Say
Bulls Say
Commercial GrowthRapid sales growth and rising reimbursed-patient numbers indicate expanding adoption of IMCIVREE across approved populations. Continued prescriber activation, payer coverage gains, and specialty commercial execution could support durable revenue expansion over the next several quarters.
Pipeline And Market ExpansionPositive early RM-718 efficacy, planned Phase III development, and geographic expansion broaden Rhythm’s future opportunity beyond its current commercial base. Patent protection extending past 2040 may also support a lengthy period for developing and commercializing MC4R therapies.
Gross Margin And LiquidityVery high product-level margins show attractive economics for IMCIVREE, while substantial liquidity provides time to invest in commercialization and clinical programs. The reported runway reduces immediate financing pressure as Rhythm works toward greater scale and operating leverage.
Bears Say
Persistent Operating LossesRhythm’s strong revenue growth has not yet translated into profitability, with substantial operating expenses producing deeply negative operating and net margins. Until commercial scale absorbs R&D and SG&A spending, earnings remain vulnerable and the path to sustainable profits is uncertain.
Negative Cash GenerationOngoing negative operating and free cash flow means Rhythm is not yet self-funding its business, even though cash burn has improved versus prior periods. Continued investment in launches and trials may require additional capital, creating financing and potential dilution pressure.
Diagnosis And Access BarriersThe commercial opportunity depends on identifying rare-disease patients and obtaining reimbursement, but underdiagnosis and lengthy specialist access can delay treatment. These structural hurdles may slow conversion of launch interest into prescriptions and extend the timeline for realizing market potential.
Rhythm Pharmaceuticals News
RYTM FAQ
What was Rhythm Pharmaceuticals Inc’s price range in the past 12 months?
Rhythm Pharmaceuticals Inc lowest stock price was $74.50 and its highest was $122.20 in the past 12 months.
What is Rhythm Pharmaceuticals Inc’s market cap?
Rhythm Pharmaceuticals Inc’s market cap is $5.93B.
When is Rhythm Pharmaceuticals Inc’s upcoming earnings report date?
Rhythm Pharmaceuticals Inc’s upcoming earnings report date is Nov 10, 2026 which is in 22 days.
How were Rhythm Pharmaceuticals Inc’s earnings last quarter?
Rhythm Pharmaceuticals Inc released its earnings results on Aug 04, 2026. The company reported -$0.73 earnings per share for the quarter, beating the consensus estimate of -$0.807 by $0.077.
Is Rhythm Pharmaceuticals Inc overvalued?
According to Wall Street analysts Rhythm Pharmaceuticals Inc’s price is currently Undervalued.
Does Rhythm Pharmaceuticals Inc pay dividends?
Rhythm Pharmaceuticals Inc does not currently pay dividends.
What is Rhythm Pharmaceuticals Inc’s EPS estimate?
Rhythm Pharmaceuticals Inc’s EPS estimate is -0.71.
How many shares outstanding does Rhythm Pharmaceuticals Inc have?
Rhythm Pharmaceuticals Inc has 68,852,080 shares outstanding.
What happened to Rhythm Pharmaceuticals Inc’s price movement after its last earnings report?
Rhythm Pharmaceuticals Inc reported an EPS of -$0.73 in its last earnings report, beating expectations of -$0.807. Following the earnings report the stock price went up 2.919%.
Which hedge fund is a major shareholder of Rhythm Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in RYTM
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Rhythm Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$146.38 (29.14% Upside)
$146.38 (29.14% Upside)
Blogger Sentiment
Bullish
RYTM Sentiment 86%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Decreased
By 142.4K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 1.5%
Last 30 Days ▲ 1.5%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-22.49%
12-Months-Change
Fundamentals
Return on Equity
-80.48%
Trailing 12-Months
Asset Growth
17.31%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Rhythm Pharmaceuticals Inc
Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.
RYTM Company Deck
RYTM Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a largely positive commercial and scientific momentum: robust early U.S. launch metrics for IMCIVREE in acquired hypothalamic obesity, 19% sequential product sales growth, encouraging RM-718 early efficacy comparable to existing MC4R agonists, NEJM coverage, and planned international rollouts (Japan and Europe). Key challenges include a one‑time France revenue charge, higher SG&A and continued GAAP losses, some tolerability-related discontinuations in RM-718, and ongoing diagnosis/access constraints that could temper uptake timing. On balance, the growth and pipeline derisking signals materially outweigh the near-term financial and operational headwinds.View all RYTM earnings summariesRYTM Stock 12 Month Forecast
Average Price Target
$146.38
▲(29.14% Upside)
Technical Analysis
uniQure
―
Viking Therapeutics
―
Structure Therapeutics, Inc. Sponsored ADR
―
MBX Biosciences, Inc.
―
Kailera Therapeutics, Inc.
―
Ownership Overview
0.78% Insiders
31.27% Mutual Funds
0.63% Other Institutional Investors
50.25% Public Companies and
Individual Investors